This inventor holds 14 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Benzene Compounds. Top assignees: Epizyme, Inc., Eisai R&d Management Co., Ltd.. Active years: 2013-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
14 out of 159 
1 out of 530 
Years Active: 2013-2024
Areas of Expertise:
Title: The Innovative Mind of Syuji Shirotori: A Journey Through Patents and Collaborations
Introduction: Syuji Shirotori is a notable inventor based in Tsukuba, Japan, with an impressive portfolio of 14 patents. His work primarily focuses on the development of novel aryl- or heteroaryl-substituted benzene compounds, which hold significant promise in the field of pharmaceutical science and cancer treatment.
Latest Patents: Among his latest patents, Shirotori has contributed to the invention of aryl- or heteroaryl-substituted benzene compounds. These innovative compounds are not only integral to the formulation of pharmaceutical compositions but also play a critical role in treating cancer. The invention outlines methods for administering these compounds and compositions to subjects in need, as well as potential applications for research or other non-therapeutic purposes.
Career Highlights: Syuji Shirotori's professional journey includes significant contributions at renowned organizations such as Epizyme, Inc. and Eisai R&D Management Co., Ltd. His work has been a driving force behind the development of treatments that leverage the therapeutic potential of his patented compounds.
Collaborations: Throughout his career, Shirotori has collaborated with talented peers like Kevin Wayne Kuntz and Masashi Seki. These collaborations have bolstered his research initiatives and enhanced the impact of his innovative contributions to the field.
Conclusion: Syuji Shirotori exemplifies the spirit of innovation and collaboration within the realm of drug development. His patents and contributions not only advance pharmaceutical applications but also reflect the potential for breakthroughs in cancer treatment. As he continues his work, the scientific community eagerly anticipates the future advancements that will emerge from Shirotori’s innovative mind.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile